SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The company disclosed quarterly financial results for Q2 2026 ended June 30, 2026, including net sales, gross margin, operating income, net income, and EPS metrics, along with revised full-year 2026 guidance for adjusted EPS.
View raw filing on EDGAR →The Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on September 3, 2026, to shareholders of record as of August 20, 2026.
View raw filing on EDGAR →Somnigroup released an updated investor presentation on August 6, 2026, disclosing strategic direction, operational performance, and forward guidance. While the presentation covers multiple business segments (Mattress Firm, Tempur Sealy, Dreams) and includes financial outlook, the Item 7.01 disclosure itself is a routine investor relations communication. However, the presentation's substantive content—including the pending Leggett & Platt acquisition (announced April 2026, expected to close by year-end 2026), 2026 financial guidance ($7.6B sales, $3.00 adjusted EPS midpoint), and long-term targets through 2028—constitutes material operational and strategic information that would affect a reasonable investor's assessment. The disclosure is primarily operational/strategic rather than fitting a specific event category (not M&A announcement, not earnings release, not a governance event), making operational_other the most appropriate classification.
View raw filing on EDGAR →The filing discloses a "Capital Value Restoration Plan" with multiple capital-structure initiatives: a $5.00 conversion price floor for existing convertible notes, weekly conversion disclosures, pursuit of equity financing instead of convertible notes, and liability reduction targets. While the plan touches on debt structure (convertible notes) and potential dilution, it is primarily a strategic capital-management and investor-confidence initiative rather than a discrete financial event (debt issuance, covenant breach, or dilutive issuance). The forward-looking language and emphasis on transparency and shareholder protection suggest this is a material governance/strategic disclosure, but it does not fit neatly into a single taxonomy category—it is neither a specific debt event, a dilutive issuance, nor a traditional governance action, making `other_material` the most appropriate classification.
View raw filing on EDGAR →The filing discloses the appointment of Scott E. Zoellner as a director of Saratoga Investment Corp., effective immediately on August 5, 2026. The Board increased from five to six members and appointed Mr. Zoellner to the audit, compensation, and nominating and corporate governance committees. This is a clear executive appointment under Item 5.02, and the addition of an independent director with significant private equity and capital markets experience is material to investors' assessment of the company's governance and oversight.
View raw filing on EDGAR →This press release discloses a material acquisition/merger in progress: Check-Cap Ltd.'s proposed business combination with MBody AI Corp. The disclosure updates the expected closing timeline to the third quarter of 2026, reports completion of shareholder approvals from both companies, and confirms filing of the Form F-1 registration statement on July 24, 2026. The merger represents a strategic transformation and change of control, with Check-Cap shareholders acquiring an operating robotics business. This is a classic Item 1.01 / 2.01 M&A activity disclosure material to investors.
View raw filing on EDGAR →Ricardo Chagas has resigned from his positions as Chief Executive Officer and Chief Financial Officer of Ambipar Response, effective immediately. While the announcement also mentions the appointment of Dennys Spencer as Interim CEO and CFO, the principal disclosed action is the departure of the CEO/CFO, making this an executive departure event. The simultaneous appointment is secondary to the resignation announcement.
View raw filing on EDGAR →Blackstone Secured Lending Fund issued a press release on August 6, 2026, announcing its second quarter 2026 financial results, including net investment income of $174 million ($0.75 per share), net asset value of $25.53 per share, and a declared dividend of $0.77 per share. The detailed presentation is furnished as Exhibit 99.1 and discloses comprehensive quarterly operating results, portfolio activity, and balance sheet metrics—the hallmark of an earnings release under Item 2.02.
View raw filing on EDGAR →Arbe Robotics announced Q2 2026 financial results with revenues of $0.7 million (vs. $0.3 million in Q2 2025) and net loss of $9.1 million (vs. $10.2 million in Q2 2025). The company provided full-year 2026 guidance of $4–6 million in revenue and adjusted EBITDA loss of $28–31 million.
View raw filing on EDGAR →Arbe Robotics appointed Assaf Pereg, CPA, as Chief Financial Officer, effective August 30, 2026, succeeding departing CFO Karine Pinto-Flomenboim.
View raw filing on EDGAR →This press release announces a registered direct offering of 8 million ordinary shares and 8 million warrants at $1.00 per unit, raising approximately $8 million gross proceeds. The offering is a registered direct placement under the company's Form F-3 shelf registration, representing a dilutive equity issuance to a single institutional investor. The warrant component (exercisable at $1.15, expiring five years from closing) adds further dilution potential. This is a material capital-raising event for a medical imaging company with acknowledged going-concern risks mentioned in the forward-looking statements.
View raw filing on EDGAR →Olenox Industries disclosed a notice from Nasdaq regarding failure to satisfy the periodic filing requirement (Listing Rule 5250(c)(1)) due to late Form 10-K and Form 10-Q filings. The company regained compliance after filing the delinquent reports, with Nasdaq confirming restoration of compliance on August 4, 2026.
View raw filing on EDGAR →The filing discloses an amendment to senior secured convertible promissory notes dated August 5, 2026, in which the "Floor Price" was reduced from $0.30 to $0.22. While technically an amendment to existing debt rather than a new issuance, the material modification of conversion terms on convertible debt instruments affects the registrant's direct financial obligations and equity dilution potential. The significant downward adjustment of the floor price suggests financial stress and increased dilution risk to existing shareholders, warranting classification as a material debt-related event.
View raw filing on EDGAR →The filing discloses a press release announcing a conference call scheduled for August 12, 2026, to discuss the Company's "financial results for the second quarter of 2026 ended June 30, 2026." Although the actual earnings results are not yet disclosed in this 8-K (they will be discussed on the call), the announcement of the earnings call and the attached press release constitute an earnings release disclosure under Item 7.01 (Regulation FD Disclosure). This is a material event as it signals the imminent disclosure of quarterly financial results to investors.
View raw filing on EDGAR →The disclosure announces that the SEC declared effective the Form F-4 registration statement on August 5, 2026, relating to the proposed business combination between Bleichroeder Acquisition Corp. II and Pasqal Holding SAS. This is a material milestone in a merger transaction—the registration statement effectiveness is a critical step toward consummation of the business combination. The filing explicitly states this is "an important step toward completion of the previously announced business combination" and notes the shareholder meeting is scheduled for August 25, 2026.
View raw filing on EDGAR →The filing discloses a change in the Company's independent registered public accounting firm, with M&K CPAS, PLLC ceasing service effective August 4, 2026, and EisnerAmper LLP being engaged as the new auditor for fiscal year ending March 31, 2027. This is a classic auditor change under Item 4.01. While the prior auditor's reports contained no adverse opinions or disclaimers, they did include an explanatory paragraph regarding going-concern uncertainty, which is material context but does not change the primary event classification.
View raw filing on EDGAR →Pono Capital Four announced execution of a definitive Merger Agreement with Blackstar Orbital Technologies Corporation on August 6, 2026. The transaction values Blackstar Orbital at $380 million and involves a merger structure where Blackstar Orbital will merge with a Pono subsidiary and continue as a wholly owned subsidiary, with Pono subsequently changing its name to Blackstar Orbital Corporation. This is a material acquisition/change of control transaction requiring shareholder approval and expected to close in Q1 2027.
View raw filing on EDGAR →The press release announces results of an Extraordinary General Meeting held on July 31, 2026, where shareholders approved a share consolidation (8-to-1) and reclassification of shares into Class A and Class B shares with differential voting rights. This is a material capital structure change approved by shareholder vote, affecting share par value, authorized capital, voting rights, and trading symbol/CUSIP, effective August 11, 2026.
View raw filing on EDGAR →NeuroSense announced completion of the Pre-NDS process with Health Canada and a December 2026 filing target for PrimeC's New Drug Submission in ALS. This is a material regulatory milestone—successful alignment with a foreign health authority on submission content and structure—that advances the company's lead therapeutic candidate toward potential commercialization. While not a discrete event type like M&A or exec change, this operational/regulatory progress is material to investors assessing the company's clinical development trajectory and near-term catalysts.
View raw filing on EDGAR →This press release announces a key clinical development milestone: DSMB unanimous approval to advance Clearmind's Phase I/II trial of CMND-100 from Part A (healthy participants) to Parts B and C, with Part B marking the first evaluation in AUD patients. This is a material operational/clinical milestone for a clinical-stage biotech company, as it represents meaningful progress in the regulatory pathway and de-risks the clinical program. The language ("key milestone," "important milestone," advancement to patient population) and the involvement of leading clinical sites (Johns Hopkins, Yale) underscore materiality to investors assessing the company's development trajectory.
View raw filing on EDGAR →The filing discloses the dismissal of Simon & Edward, LLP as the independent registered public accounting firm and engagement of Kreit & Chiu CPA LLP effective August 1, 2026. This is a direct auditor change under Item 4.01. The materiality is heightened by the disclosure that the prior auditor's reports contained explanatory paragraphs regarding going-concern doubts for fiscal years 2024 and 2025, and material weaknesses in internal control over financial reporting were identified.
View raw filing on EDGAR →This is an investor presentation disclosing Psyence BioMed's clinical development strategy, portfolio progress, and strategic positioning in psychedelic therapeutics. The presentation highlights material operational milestones including Phase IIb trial enrollment in Australia (87 patients dosed with NPX-5 for Adjustment Disorder in cancer palliative care), FDA Pre-IND feedback received, and the company's vertically integrated platform through its strategic equity stake in PsyLabs. While the presentation contains forward-looking statements and market opportunity discussion, the substantive disclosure concerns the company's operational and clinical development pathway, manufacturing partnerships, and regulatory progress—operational matters that would affect a reasonable investor's assessment of the company's execution capability and near-term catalysts.
View raw filing on EDGAR →The 6-K reports results of an Extraordinary General Meeting held on August 6, 2026, where shareholders voted on two resolutions: (1) authorization to the Board to issue new shares and securities, and (2) approval of a private placement of 23,000,000 new ordinary shares at KRW 1,600 per share for total proceeds of KRW 36,800,000,000 (HKD 194,698,693.20). Both resolutions passed unanimously with 100% of shares voted in favor. This is a classic shareholder vote result disclosure, and the private placement is material as it represents significant dilution and capital raising.
View raw filing on EDGAR →The 6-K discloses the results of the Company's 2026 Annual General Meeting of Shareholders held on August 4, 2026, including voting results for the election of director Michael Gray (32,997,923 votes for, 0 against, 606,743 abstain) and re-appointment of Ernst & Young LLP as independent auditor (33,591,687 votes for, 12,290 against, 689 abstain). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, with material governance outcomes.
View raw filing on EDGAR →The 6-K discloses the results of a Special General Meeting of Shareholders held on August 6, 2026, at which shareholders voted upon and approved an agenda item previously described in the Company's proxy statement filed July 2, 2026. This is a direct disclosure of shareholder vote results, matching the `shareholder_vote_results` event type. While the specific agenda item is not detailed in this body text, the filing explicitly confirms that shareholders voted and approved the matter, which is material to investors as it reflects shareholder approval of a corporate action.
View raw filing on EDGAR →The exhibit is a formal notice to shareholders announcing the declaration and payment of interim dividends for Q2 2026 in the amount of R$18,899,226.72 (R$0.06 per common or preferred share, or R$0.18 per UNIT). The notice specifies the ex-dividend date (August 17, 2026), record date (August 14, 2026), and payment date (August 28, 2026), which are the hallmarks of a dividend distribution disclosure.
View raw filing on EDGAR →This 8-K discloses the results of 60 Degrees Pharmaceuticals' 2026 Annual Stockholders Meeting held on August 5, 2026, under Item 5.07. The filing reports voting outcomes for six proposals: election of five directors, approval of a 2022 Equity Incentive Plan amendment (800,000 additional shares), approval of a reverse stock split (1:5 to 1:10 ratio), ratification of RBSM LLP as independent auditor, approval of a management success fee for a change of control/sale of Arakoda, and adjournment authority. All six proposals were approved by majority vote. These results are material to investors as they affect board composition, equity dilution, capital structure (reverse split), auditor selection, and potential management incentives in a transaction.
View raw filing on EDGAR →AEye issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing Q2 revenue of $202 thousand (up 9x year-over-year and 2x sequentially), GAAP net loss of $(10.0) million, and cash position of $71.5 million. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics and forward-looking guidance on 2026 cash consumption, making it a material earnings announcement.
View raw filing on EDGAR →The 6-K discloses the results of the Eighth Ordinary General Meeting of Shareholders held on July 24, 2026, where shareholders voted on and approved the financial statements for the eighth fiscal year (May 1, 2025 to April 30, 2026). The vote tally shows 8,325,667 votes in favor, 43,980 against, and 0 abstentions, representing approximately 24.71% of exercisable votes. This is a direct disclosure of shareholder vote results, which is material to investors as it confirms approval of the company's annual financial statements.
View raw filing on EDGAR →The press release announces that Zhengye has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after previously falling below that threshold for 30 consecutive business days (notification received May 29, 2026). While the announcement is positive (regaining compliance), it discloses a material delisting risk event—the Company was in non-compliance with a continued listing standard and faced potential delisting. The disclosure of the prior non-compliance and the path to remediation is material to investors assessing listing status and regulatory standing.
View raw filing on EDGAR →The 8-K discloses quarterly financial results for Q2 2026 under Item 2.02 (Results of Operations and Financial Condition), with a press release reporting net income of $98 million, Adjusted EBITDA of $182 million, and operating cash flow of $154 million. Item 7.01 also announces a quarterly cash distribution of $0.36 per common unit. The filing is centered on earnings disclosure and distribution announcement, which are material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →OS Therapies Inc entered into a material definitive agreement for a secured convertible promissory note (Leonite Note) of up to $10,000,000 with an initial tranche of $1,600,000 funded on July 2, 2026, and simultaneously disclosed the creation of a Bridge Note as a direct financial obligation under Regulation D exemptions, representing a material debt financing.
View raw filing on EDGAR →The filing discloses results of the Company's 2026 annual meeting of shareholders held on August 6, 2026, with detailed voting outcomes for four proposals: election of five directors, ratification of auditor (Salberg & Company), approval of an amendment to the 2021 Omnibus Equity Incentive Plan increasing reserved shares from 1,000,000 to 2,000,000, and authorization for a reverse stock split at a ratio between 1-for-2 and 1-for-25. Item 5.07 explicitly covers submission of matters to a vote of security holders, and the filing presents the final vote tallies for each proposal, making this a classic shareholder vote results disclosure.
View raw filing on EDGAR →The press release announces the appointment of Daniel Brau as Chief Quantum Officer (CQO), a newly created executive role. The appointment is material because it represents a significant strategic leadership decision tied to the company's quantum commercialization strategy, with Brau given a mandate to lead strategic and commercial development of the SEALQuantum ecosystem and drive revenue generation across the quantum portfolio. This is a clear executive appointment disclosure.
View raw filing on EDGAR →The Company issued 426,848 shares of Common Stock (with an additional 5,184 shares pending issuance) to satisfy an earn-out obligation under the Prevu acquisition merger agreement. The shares were issued pursuant to Section 4(a)(2) and Rule 506 of Regulation D as an unregistered private placement to accredited investors. This is a classic dilutive issuance under Item 3.02, representing a material increase in share count (approximately 7.3% dilution based on the post-issuance outstanding count of 5,861,724 shares) and a direct financial obligation satisfied through equity rather than cash.
View raw filing on EDGAR →Solmate Infrastructure announced the acquisition of 1,001 additional SOL tokens, increasing its total holdings to approximately 1.26 million SOL. This represents a material capital deployment and strategic asset acquisition that affects the company's balance sheet and treasury position. While not a traditional M&A transaction (which typically involves acquisition of operating businesses or significant equity stakes in other companies), this digital asset acquisition is a material financial event reflecting the company's core business strategy of building a digital asset treasury and institutional gateway to the Solana ecosystem.
View raw filing on EDGAR →The filing discloses that Larry Ellis resigned as a member of the Board of Directors on July 31, 2026, with explicit statement that the resignation was not due to disagreement. While the filing also mentions board compensation approval on August 1, 2026, the principal disclosed event is the director departure. The resignation of a board member is material to investors' assessment of governance and board composition.
View raw filing on EDGAR →This is a press release announcing Metalpha's audited financial results for the fiscal year ended March 31, 2026, disclosing revenue of $37.1 million, continued profitability, and total assets of $485.6 million. The Company explicitly states it "filed its annual report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission (the 'SEC') on Aug 6, 2026," confirming this is an earnings announcement tied to the annual financial filing. Material to investors assessing the registrant's financial performance and position.
View raw filing on EDGAR →Relmada Therapeutics reported Q2 2026 financial results, including a net loss of $12.9 million, R&D expenses of $8.4 million, and cash balance of $217.7 million, along with a business update on pipeline programs (NDV-01, sepranolone) and corporate developments.
View raw filing on EDGAR →This press release announces MBody AI's expansion into outdoor autonomous services through exclusive U.S. distribution rights for outdoor cleaning robots in gaming and hospitality across six states. The disclosure describes a material commercial milestone—securing exclusive distribution rights, expanding addressable market, and launching a new service line with an existing major customer pilot—that would affect a reasonable investor's assessment of the combined company's growth prospects and revenue potential. While the underlying business combination itself is a material acquisition event, this exhibit focuses on the operational and commercial progress of MBody AI's business expansion rather than the M&A transaction mechanics, making `operational_other` the most precise classification.
View raw filing on EDGAR →The filing discloses non-reliance on previously issued unaudited condensed consolidated financial statements for three quarterly periods (Q1, Q2, Q3 2025) due to a material measurement error in the acquisition-date fair value of Series A Preferred Stock issued in the NAHD merger. The error of $15.77 million affected goodwill and stockholders' equity calculations under ASC 805 and ASC 250, requiring restatement of the affected periods. Management has concluded the prior statements should no longer be relied upon and is amending and restating them.
View raw filing on EDGAR →The filing discloses two departures: Erick Soto's resignation as Chief Product Officer (effective August 5, 2026) and Kunal Mehta's resignation as a director and committee member (effective August 7, 2026). While the filing also mentions appointments of Ram Menghani and Michael Koehneman to committees, the principal disclosed actions center on the departures of named executives and a director. The departure of a CPO and board member are material events affecting the registrant's leadership structure.
View raw filing on EDGAR →The press release announces Hitek's entry into a Share Purchase Agreement to acquire Ju Fu Limited, an advertising and digital marketing company, for an aggregate purchase price of US$20,000,000 in cash and equity consideration. This is a material acquisition that expands the Company into new business segments, with first closing expected August 11, 2026. The transaction clearly falls under Item 1.01 (Material Agreements) and Item 2.01 (Completion of Acquisition or Disposition) of 8-K disclosure requirements.
View raw filing on EDGAR →The filing discloses the appointment of Dr. Christopher Kim as Chief Scientific Officer, effective immediately on August 5, 2026. As CSO, he will lead scientific, clinical, and regulatory development of the Company's primary APITOX program. This is a material executive appointment to a senior leadership role overseeing the company's core development strategy and regulatory pathway.
View raw filing on EDGAR →Columbus Acquisition Corp entered into a First Amendment to the business combination agreement with WISeSat.Space Holdings Corp. and WISeSat.Space Corp., extending the Outside Date to October 31, 2026. The amendment modifies the material definitive agreement governing the proposed merger involving SPAC Columbus Acquisition Corp, target WISeSat.Space Corp., and sellers WISeKey and SEALSQ.
View raw filing on EDGAR →Good Times Restaurants Inc. issued a press release on August 6, 2026, announcing financial results for fiscal 2026 third quarter ended June 30, 2026, including total revenues of $35.2 million, net income attributable to common shareholders of $1.9 million, and same-store sales metrics for both brand segments. This is a standard quarterly earnings disclosure filed under Item 2.02 with the press release attached as Exhibit 99.1, containing detailed financial statements and management commentary.
View raw filing on EDGAR →The news release announces final TSX Venture Exchange approval and receipt of funds from a "non-brokered private placement" previously disclosed on July 16, 2026. Non-brokered private placements are unregistered equity issuances that dilute existing shareholders. The announcement confirms completion of the offering and receipt of proceeds, making this a material capital-raising event typical of small-cap issuers.
View raw filing on EDGAR →The filing discloses the completed sale of the Hyatt Regency Long Island hotel property for approximately $26.5 million in cash on July 31, 2026, pursuant to an Agreement of Purchase and Sale dated April 8, 2026. This is a material disposition of a hotel asset by Ashford Hospitality Trust, a REIT, and directly falls under Item 2.01 (Completion of Acquisition or Disposition of Assets). The pro forma financial statements confirm removal of a 358-room hotel generating approximately $21.3 million in annual revenue and show the company used proceeds to repay approximately $25.7 million of mortgage debt secured by a 15-hotel portfolio.
View raw filing on EDGAR →Nelnet issued a press release on August 6, 2026 disclosing GAAP net income of $66.7 million ($1.85 per share) for Q2 2026 versus $181.5 million ($4.97 per share) in Q2 2025, along with detailed segment results, financial statements, and forward-looking guidance. This is a standard quarterly earnings release attached as Exhibit 99.1 to Item 2.02, which is the designated Item for results of operations and financial condition disclosures.
View raw filing on EDGAR →Item 2.02 discloses Assured Guaranty Ltd.'s second quarter 2026 financial results via press release (Exhibit 99.1), reporting net income of $39 million ($0.88 per share), adjusted operating income of $55 million ($1.23 per share), and gross written premiums of $81 million. The filing explicitly states the press release reports "second quarter 2026 results," which is a standard quarterly earnings release material to investors assessing the company's financial performance.
View raw filing on EDGAR →